1. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 62

    Overview of in vitro methods used to assess e-cigarettes based on “Toxicity Testing in 21st Century” principles

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); WALELE T.(2)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    When the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy” a new toxicological paradigm was created, focusing on the use of human cell lines and the disruption of key cellular pathways. In keeping with ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 08

    Indoor air quality and surface deposition assessment following use of an open system e-cigarette

    BAUER N.(1); TSCHIERSKE N.(1); O'CONNELL G.(2); CAHOURS X.(3)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands; (3) SEITA-Imperial Tobacco Limited, Fleury-les-Aubrais, France
    Electronic cigarette (e-cigarette) nicotine delivery devices are growing in popularity worldwide. Both regulators and public health organisations are beginning to examine potential implications that exposure to exhaled e-cigarette aerosol may have on non ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “ Toxicity Testing in the 21st Century: A Vision and a Strategy ”, Fontem Ventures B.V. have investigated the utility of a series of endpoints ...